StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.52−4.33 (-3.44%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Kymera Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Kymera Therapeutics's price to sales ratio was 106.3× on Nov 11, 2026, against 111.3× a year earlier. Over the last 5 years it ranged from 11.6× to 189.5×, with a median of 34.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026106.3×−21.3
2025Dec 31, 2025127.6×+97.9
2024Dec 31, 202429.7×−0.4
2023Dec 29, 202330.1×+0.4
2022Dec 30, 202229.7×−16.5
2021Dec 31, 202146.3×−73.1
2020Dec 31, 2020119.4×–

More Kymera Therapeutics figures

See a number that looks wrong?